Annovis Bio (ANVS) Expected to Announce Earnings on Friday

Annovis Bio (NYSE:ANVS) is projected to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.

Annovis Bio (NYSE:ANVS) last released its quarterly earnings data on Friday, March 21st. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). During the same period in the previous year, the business posted ($0.43) EPS. On average, analysts expect Annovis Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Annovis Bio Stock Down 0.5 %

Shares of ANVS stock opened at $1.84 on Friday. The company has a market cap of $26.19 million, a P/E ratio of -0.41 and a beta of 1.65. The business has a 50 day moving average of $2.76 and a two-hundred day moving average of $5.59. Annovis Bio has a 52 week low of $1.53 and a 52 week high of $20.00.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital restated a “hold” rating on shares of Annovis Bio in a research report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $37.00.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.